Fundraising FoxTOLREMO Therapeutics AG
2 known investors
Find your way into TOLREMO Therapeutics AG
Sign up to see every warm intro you have to TOLREMO Therapeutics AG
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TOLREMO Therapeutics AG team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
Investors · 2
BioMedPartnerslisted by BioMedPartnersBasel · $648K – $6.5M
How we know: BioMedPartners's portfolio page · the VCSheet dataset · Not right? Tell us
redalpinereportedZug · $108K – $2.2M
How we know: the VCSheet dataset · Not right? Tell us
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Terremoto BiosciencesTerremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry. It pursues both best-in-class treatments against known drug targets and first-in-class medicines against previously undruggable targets.
Companies working in the same space as TOLREMO Therapeutics AG.
Frequently asked questions
- What does TOLREMO Therapeutics AG do?
- TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.
- Who are TOLREMO Therapeutics AG's investors?
- TOLREMO Therapeutics AG's investors include BioMedPartners, redalpine.